Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
labetuzumab
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Labetuzumab is a humanized monoclonal antibody that specifically targets CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), a glycoprotein overexpressed on the surface of various cancer cells, most notably in colorectal carcinoma. By binding to CEACAM5, labetuzumab can inhibit tumor growth and mediate immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC). It has been investigated primarily for use in radioimmunotherapy and as part of experimental targeted therapies for cancers expressing CEACAM5. Labetuzumab’s precise targeting allows it to deliver cytotoxic agents directly to malignant cells while sparing healthy tissue, potentially reducing side effects compared with conventional chemotherapy[1][2][6].
- Other names
- labetuzumab
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on labetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on labetuzumab.